Pulmatrix Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly3.3MTarget: Sufficient capital to fund operations and complete the reverse merger
Net Loss Quarterly-1.2MTarget: Narrowing losses through cost-containment and strategic wind-downs
Shares Outstanding Quarterly3.7MTarget: Maintain stable capital structure prior to reverse merger exchange ratio execution
Watch Items
- Eos SENOLYTIX Reverse Merger ConsummationTrigger: Stockholder approval and SEC Form S-4 registration statement effectivenessAction: Monitor SEC filings for S-4 amendments, shareholder vote dates, and closing announcements expected in Q3 2026
- Going Concern Status and Cash RunwayTrigger: Cash balance falling below $2.5 million or delays in the $19 million concurrent financingAction: Evaluate alternative financing options, asset sales of iSPERSE™ technology, or potential board-led dissolution and liquidation
- PTC-2105 Clinical Development MilestonesTrigger: Initiation of clinical trials for sarcopenia and sarcopenic obesity under the combined entityAction: Track clinical trial registry updates and corporate presentations post-merger
Research as of 20 Jun 2026